Stockreport

XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab

XOMA Corporation  (XOMA) 
Last xoma corporation earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investors.xoma.com/investor-relations
PDF – Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a share of milestones and r [Read more]